+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

France Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • PDF Icon

    Report

  • 80 Pages
  • February 2024
  • Region: France
  • Mordor Intelligence
  • ID: 5854259
The France Diabetes Devices Market size is estimated at USD 1.30 billion in 2024, and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the coronavirus disease-2019 (COVID-19) pandemic epidemic. Diabetes has previously been identified as a significant risk factor for death in individuals infected with either the Middle East respiratory syndrome-related coronavirus (MERS-CoV) or the 2009 H1N1 pandemic influenza. More recently, one of the main comorbidities linked to COVID-19 has consistently been diabetes.

Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region. According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people. Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all of the countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.

France Diabetes Devices Market Trends

Monitoring Devices Hold Highest Market Share in France Diabetes Care Devices Market

In France, over a lifetime time horizon, the G6 RT-CGM system is likely to be cost-effective compared with SMBG for individuals with long-standing T1D. One of the commitments stipulated in the French National Health Strategy for 2018-2022 was to guarantee prompt and universal access to innovations such as new medical devices. However, there are increasing financial strains on many health systems, so a sizable clinical benefit that outweighs currently available technologies should be enough to justify the cost of novel technologies. In view of the incremental clinical and QoL benefits afforded by the Dexcom G6 RT-CGM system in France. As people suffering from diabetes were at an increased risk of COVID-19 infection, the French companies ensured an adequate supply of the required monitoring devices on the market to ensure the well-being of the affected citizens.

In France, the insurance plans reduce the burden on the diabetic population. However, different policies exist for both the type-1 and type-2 diabetic populations. For instance, the insurance covers up to 200-400 test strips in a year for the type-2 population, whereas for the type-1 population, it covers approximately 3,000 test strips in a year.



Increasing Diabetes Population in France Boosting the France Diabetes Devices Market during forecasting period

In France, the type-1 diabetes population increased with a CAGR greater than 3% over the forecast period.

France is one of the 59 nations in the IDF-EUR area. Moreover, in 2021, 61 million individuals in the Europe Region and 537 million people worldwide were expected to have diabetes; by 2045, this number is expected to increase to 69 million. According to a survey by the EU Commission, the number of people in France who have chronic diabetes is the highest, and one in 10 people in France suffer from diabetes. The prevalence of diabetes is significant in France, although the rules' target of 80% compliance with advised healthcare consultations isn't always met. To promote proactive therapy adjustment and decrease therapeutic inertia, new techniques that focus on patient and physician education and information are necessary to lessen the burden of complications and hospitalizations associated with diabetes. According to a 2022 article titled "Epidemiology and Health Impact of Diabetes in France," problems associated with diabetes were more common in people with diabetes type-1 than type-2 over a 5-year period (52.2 vs. 34.7%). Over a period of two years, diabetes-related admissions were also more common in diabetes type-1 patients than in diabetes type-2 patients (29.8% vs. 16.9%).

When risk factors, including obesity and a sedentary lifestyle, continue to rise in France and elsewhere, it is challenging to reverse the diabetes trend there. In order to lessen the burden of the condition, the French public health law was modified in 2020 to add two provisions that aimed to boost adherence to the advised medical monitoring of diabetes patients and reduce the incidence of complications from diabetes, with a focus on cardiovascular events. The French health authority (HAS) developed the recommended treatment routes for patients with DT1 and DT2, putting a focus on problem detection and cardiovascular risk monitoring. Despite these initiatives, the French diabetic population has struggled to accept the recommendations due to inertia.

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in France.



France Diabetes Devices Industry Overview

The new technologies in diabetes devices, like continuous glucose monitoring, have increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring device market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Monitoring Devices
5.1.1 Self-monitoring Blood Glucose Devices
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 Sensors
5.1.2.2 Durables
5.2 Management Devices
5.2.1 Insulin Pump
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
6 MARKET INDICATORS
6.1 Type-1 Diabetes population
6.2 Type-2 Diabetes population
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Becton and Dickenson
7.1.2 Medtronic
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
7.1.6 Novo Nordisk
7.1.7 Sanofi
7.1.8 Eli Lilly
7.1.9 Abbottt
7.1.10 Roche
7.1.11 Lifescan (Johnson &Johnson)
7.1.12 Dexcom
7.2 Company Share Analysis
8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Becton and Dickenson
  • Medtronic
  • Insulet
  • Tandem
  • Ypsomed
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Abbottt
  • Roche
  • Lifescan (Johnson &Johnson)
  • Dexcom

Methodology

Loading
LOADING...